

DEVELOPING FIRST-IN-CLASS THERAPEUTICS BASED ON COMPUTATIONAL TARGET DISCOVERY AND VALIDATION

Compugen is transforming the discovery and development of first-in-class therapeutics based on its proven capabilities in computational target discovery and functional validation. The Company has developed a diverse pipeline based on original targets and anticipates entering clinical trials in 2018 with its lead candidate, COM701 (anti-PVRIG mAb), for which an IND filing is anticipated towards the end of Q1 2018. Compugen has assembled a top-tier leadership team and a world-class network of advisors, including Paul Sekhri (who joined recently as Chairman of the Board), renowned cancer researcher Dr. Drew Pardoll (Chair of Compugen’s SAB), and former Bristol-Myers CSO and EVP, Dr. Elliott Sigal (Compugen strategic advisor).

NASDAQ: CGEN
TASE: CGEN.TA

Price*: \$4.00
Market Cap*: \$204.6M
Analyst Coverage: JMP Jefferies

*as of March 05, 2018

DIVERSE THERAPEUTIC PIPELINE BASED ON ORIGINAL TARGETS

Compugen’s diverse pipeline is comprised of therapeutic programs based on original targets discovered and validated by the Company, including immune checkpoint programs targeting PVRIG, TIGIT, and myeloid biology, as well as a next-generation immune tolerance induction program. In addition to four preclinical stage programs which originated from its computer prediction, Compugen continues to further substantiate its pipeline using its proprietary discovery capabilities to identify original targets and in turn validate them in collaboration with leading academic partners.

COMPUGEN’S PIPELINE

From Code to Cure™




LEAD PROGRAM NEARING THE CLINIC

COM701 is a monoclonal antibody that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen, which shed a new light on the TIGIT pathway and the importance of PVRIG/TIGIT blockade for potential cancer treatments. COM701 is synergistic with antagonist anti-PD-1 antibodies and with Compugen’s anti-TIGIT antibody, COM902, and therefore may offer first-in-class opportunities as monotherapy or as dual and triple combination therapy.

TARGETING NEW PATHWAYS AND MOAs

Compugen has played a key role in advancing the understanding of a complex set of interactions on the DNAM axis involving PVRIG and TIGIT, and the potential multiple drugs targeting this axis in combination together with a PD-1 pathway inhibitor. These discoveries, as well as additional programs being advanced by the Company, have the potential to fulfill a foundational role in advancing new cancer immunotherapies to meet the needs of patient populations non-responsive or refractory to current immune checkpoint inhibitor therapies.

ADDING MULTIPLE MECHANISMS TO BROADLY ADDRESS CANCER TREATMENT



ADDRESSING MULTIPLE IMMUNE SUPPRESSIVE COMPONENTS IN THE TME

This fact sheet contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "may," "expects," "anticipates," "believes," and "potential," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These and other factors, are more fully discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission ("SEC") as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this fact sheet and Compugen does not assume any obligation to update any forward-looking statements unless required by law.